摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-氟-4-硝基苯基)四氢吡咯 | 385380-74-5

中文名称
1-(2-氟-4-硝基苯基)四氢吡咯
中文别名
1-(2-氟-4-硝基苯基)吡咯烷
英文名称
1-(2-fluoro-4-nitrophenyl)pyrrolidine
英文别名
3-fluoro-1-nitro-4-pyrrolidinobenzene
1-(2-氟-4-硝基苯基)四氢吡咯化学式
CAS
385380-74-5
化学式
C10H11FN2O2
mdl
——
分子量
210.208
InChiKey
SMKXLBISYVJESG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    49.1
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090

SDS

SDS:bf2debad1e64395563a9acb7045dd163
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-(2-Fluoro-4-nitrophenyl)pyrrolidine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-(2-Fluoro-4-nitrophenyl)pyrrolidine
CAS number: 385380-74-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11FN2O2
Molecular weight: 210.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(2-氟-4-硝基苯基)四氢吡咯platinum(IV) oxide sodium azide 、 氢气三乙胺三苯基膦 作用下, 以 四氢呋喃甲醇N,N-二甲基甲酰胺 为溶剂, 20.0~65.0 ℃ 、196.12 kPa 条件下, 反应 22.0h, 生成 (5S)-5-(aminomethyl)-3-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1,3-oxazolidin-2-one
    参考文献:
    名称:
    恶唑烷酮抗菌剂的构效关系(SAR)研究。2.在5-硫代羰基恶唑烷酮中亲脂性与抗菌活性之间的关系。
    摘要:
    考虑到分子的疏水性参数,对5-硫代羰基恶唑烷酮抗菌剂的研究继续进行,合成了5-硫脲和5-二硫代氨基甲酸酯恶唑烷酮。结构-活性关系(SAR)研究表明,亲脂性显着影响对5-硫代羰基恶唑烷酮的抗菌活性,尤其是计算出的log P值以及5-亲水(或疏水)取代基与疏水(或亲水)之间的平衡苯环上的取代基。发现一些5-硫代羰基恶唑烷酮对革兰氏阳性细菌具有良好的体外抗菌活性,包括耐甲氧西林的金黄色葡萄球菌(MRSA)和耐万古霉素的肠球菌(VRE)。
    DOI:
    10.1248/cpb.49.353
  • 作为产物:
    描述:
    1,2-二氟苯硫酸硝酸 作用下, 以 二甲基亚砜 为溶剂, 反应 8.0h, 生成 1-(2-氟-4-硝基苯基)四氢吡咯
    参考文献:
    名称:
    含氟3-氨基-1,2,4-苯并三嗪合成中硝基参与氢亲核取代与环缩合的串联
    摘要:
    在 ButOK 存在下,3-氟-1-硝基苯与盐酸胍在 THF 中的反应得到异构的含 5-和 7-氟的 3-氨基-1,2,4-苯并三嗪。
    DOI:
    10.1007/s11172-006-0406-9
点击查看最新优质反应信息

文献信息

  • Design and Synthesis of Novel 5-Acetylthiomethyl Oxazolidinone Analogs
    作者:Lei Chen、Jian-Wei Wang、Li Hai、Guang-Ming Wang、Yong Wu
    DOI:10.1080/00397910902756197
    日期:2010.2.26
    The oxazolidinone class of antimicrobial agents represents a promising advance in the fight against resistant Gram-positive bacterial infections. To improve antibacterial activity and expand the spectrum of activity including Gram-negative bacteria, a series of novel 5-acetylthiomethyl oxazolidinone analogs were designed and synthesized based on the structure–activity relationship studies. The structures
    恶唑烷酮类抗微生物剂代表了在对抗耐药革兰氏阳性细菌感染方面的一个有希望的进步。为了提高抗菌活性并扩大包括革兰氏阴性菌在内的抗菌谱,基于结构-活性关系研究,设计并合成了一系列新型 5-乙酰硫甲基恶唑烷酮类似物。目标化合物和主要中间体的结构经1H NMR、13C NMR、红外(IR)、质谱(MS)和元素分析确证。
  • [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
    申请人:SUNSHINE LAKE PHARMA CO LTD
    公开号:WO2014012360A1
    公开(公告)日:2014-01-23
    The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
    本发明涉及医学领域,提供了新型含氮杂环化合物,其制备方法及其作为药物的用途,特别是用于治疗和预防组织纤维化。还提供了含有这些含氮杂环化合物的药用可接受的组合物,以及这些组合物在治疗人类或动物组织纤维化方面的用途,特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
  • Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
    申请人:SUNSHINE LAKE PHARMA CO., LTD.
    公开号:US20150087639A1
    公开(公告)日:2015-03-26
    The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
    本发明涉及医学领域,提供了新颖的含氮杂环化合物,其制备方法及其作为药物的用途,特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物,以及这些组合物在治疗人类或动物组织纤维化方面的用途,特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
  • Aryl Urea Derivatives for Treating Obesity
    申请人:Bloxham Jason
    公开号:US20080261952A1
    公开(公告)日:2008-10-23
    A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.
    通过向需要此类治疗的受试者施用有效量的芳基脲CB-1受体调节化合物来治疗与CB-1受体相关的疾病,尤其是肥胖症的方法。
  • Nitrogenous heterocyclic derivatives and their application in drugs
    申请人:SUNSHINE LAKE PHARMA CO., LTD.
    公开号:US09434695B2
    公开(公告)日:2016-09-06
    The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
    本发明涉及医学领域,提供了新型的含氮杂环化合物,其制备方法以及作为药物的用途,尤其是用于治疗和预防组织纤维化。本发明还提供了包含该含氮杂环化合物的药学上可接受的组合物,以及在人类或动物组织纤维化治疗中使用该组合物的用途,尤其是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、手术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化症、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化等方面的用途。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦